Global healthcare company Viatris Inc (Nasdaq:VTRS) announced on Tuesday the appointment of Matthew J Maletta as chief legal officer (CLO), effective 9 February 2026.
This follows the transition of the company's current CLO, Brian Roman, after more than 20 years with Viatris and its predecessor company, Mylan. Roman will stay on through 1 April 2026, to ensure a smooth transition.
Maletta has nearly 30 years of legal experience and expertise in leading legal teams for both generic and branded pharmaceutical companies. From 2015 to 2025, he served as executive vice president, chief legal officer and corporate secretary at Endo, where he oversaw Endo's merger with Mallinckrodt and the subsequent spin-off of Par Health.
Earlier, Maletta spent over a decade in the legal department at Allergan, rising to vice president, associate general counsel and corporate secretary.
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic